A vascular closure device with improved safety and ductal hemostasis.
The vascular closure device, made of bioabsorbable materials, utilizes a combination of anchors, caps, and sutures to achieve rapid and safe hemostasis, solving the problems of time-consuming and complication-prone manual compression techniques and reducing the risk of thrombosis.
Patent Information
- Application Number
- CN202180069706.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-10-01
- Filing Date
- 2021-10-02
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2041-10-02
AI Technical Summary
Existing manual compression techniques for hemostasis are time-consuming, rely on clot formation, are uncomfortable, and can lead to complications, especially with increased risks when using anticoagulants. Traditional devices may leave intravascular components, leading to residual bleeding.
The device employs a closure mechanism consisting of an intravascular anchor, an outer cap, and sutures made of bioabsorbable materials. The anchor is fixed to the vessel wall, the outer cap is sealed, and rapid hemostasis is achieved through the interference of sealant and sutures or adhesive. The device is biodegradable and absorbable after use.
It achieves rapid and safe hemostasis, reduces the risk of complications, simplifies the treatment process, reduces patient discomfort, and reduces the possibility of thrombosis during the drug's action period.
Smart Images

Figure CN116234502B_ABST
Abstract
Description
[0001] Related applications
[0002] This application claims the benefit and priority of U.S. Nonprovisional Patent Application No. 17 / 492,418, filed October 1, 2021, which claims the benefit and priority of U.S. Provisional Patent Application No. 63 / 090,556, filed October 12, 2020, and U.S. Provisional Patent Application No. 63 / 114,202, filed November 16, 2020, the entire disclosure of which is incorporated herein by reference. background 1. Technical Field
[0004] This disclosure generally relates to systems, apparatus, and methods for occluding openings in body cavities. More specifically, this disclosure relates to techniques for percutaneous closure of arterial and venous perforation sites, which are typically accessed through tissue channels. 2. Background Technology
[0006] Many diagnostic and interventional vascular procedures are now performed transluminally. A catheter is introduced into the vascular system at a convenient access location and guided through the system to the target location using established techniques. This procedure requires vascular access, typically established using the well-known Seldinger technique. Vascular access is usually provided via a guide sheath positioned to extend from outside the patient into the vascular lumen. When vascular access is no longer needed, the guide sheath is removed and bleeding at the perforation site is stopped.
[0007] A common method for achieving hemostasis (stopping bleeding) is to apply external force near and upstream of the perforation site, typically by manual compression. This method has several drawbacks. For example, the manual compression procedure is time-consuming, often requiring half an hour or more of compression before hemostasis is achieved. Additionally, this compression technique relies on clot formation, which can be delayed until the anticoagulant used in vascular treatment procedures (such as heart attack, stent deployment, non-optical PTCA results, etc.) dissipates. Anticoagulants can take two to four hours to dissipate, further increasing the time required before the manual compression procedure can be completed.
[0008] Manual compression is uncomfortable for patients and often requires analgesia to tolerate. Furthermore, applying excessive pressure can sometimes completely block the underlying vessel, leading to local ischemia and / or thrombosis. After manual compression, patients typically remain lying down under close observation for four to twelve hours or longer to ensure continued hemostasis. During this period, rebleeding may occur, leading to blood loss through the catheter, hematoma and / or pseudoaneurysm formation, and arteriovenous fistula formation. These complications may require blood transfusions and / or surgical intervention.
[0009] The incidence of complications from manual compression procedures increases when the guide sheath size increases and / or when patients are anticoagulated. Compression techniques used for arterial closure can be risky and are expensive and strenuous for patients. Although the risk of complications can be reduced by using trained individuals, engaging such personnel in this work is both costly and inefficient. However, with the increasing number and effectiveness of transluminal diagnostic and interventional vascular procedures, the number of patients requiring vascular puncture for effective hemostasis continues to rise.
[0010] The introduction of vascular closure devices reduces hemostasis time, enabling earlier ambulation and improving patient comfort. Initially, devices focused on techniques involving sutures or collagen plugs. However, while these techniques seal the opening or perforation site, they often leave intravascular components in the blood vessel, which can lead to complications and cause residual bleeding or catheter leakage. A certain amount of slow, steady catheter bleeding is common. This bleeding usually requires direct management by a trained healthcare professional until it stops completely. Anticoagulants, often administered to patients with inserted catheters, can exacerbate bleeding and may require manual compression to manage until the medication dissipates. Summary of the Invention
[0011] This application relates to a vascular closure device for rapid hemostasis at perforation sites in the vessel wall. The vascular closure device may include: an intravascular anchor having one or more suture attachment points; an outer vascular cap having an inner lumen; a sealant; and a suture connected to at least one of the one or more suture attachment points of the intravascular anchor and passing through the inner lumen of the outer vascular cap. Each of the intravascular anchor, outer vascular cap, sealant, and suture may be formed of a bioabsorbable material.
[0012] This invention relates to a vascular closure device for immediate hemostasis at a perforation site in a blood vessel wall. The closure device comprises: an intravascular anchor having one or more suture attachment points; an outer vascular cap having an inner lumen; a sealant; and a suture connected to at least one of the one or more suture attachment points of the intravascular anchor, passing through the inner lumen of the outer vascular cap and through the sealant to connect the intravascular anchor to the outer vascular cap and the sealant. Each of the intravascular anchor, outer vascular cap, sealant, and suture is formed of a bioabsorbable material.
[0013] The present invention also relates to a vascular closure device having one or more elongated bodies having a flexible member and a keel (optionally having a plurality of ribs radiating from the keel to a raised edge of the elongated body); a vascular cap formed of an elastomeric material; a sealant formed of polyethylene glycol (PEG); a suture having a distal suture portion and a proximal suture portion, the diameter of the inner lumen of the vascular cap being smaller than the diameter of the distal suture portion, and an inner vascular anchor formed of or having a material selected from polyglycolic acid (PGA), poly-L-lactic acid (PLLA), polycaprolactone (PCL), poly-DL-lactic acid (PDLLA), polytrimethylene carbonate (PTMC), and polydioxanone (PPDO), and the sealant being expandable to four times its original size when introduced into a fluid.
[0014] A vascular closure device for immediate hemostasis at a perforation site in a blood vessel wall, the device comprising: an intravascular anchor having one or more suture attachment points; an external vascular cap having an inner lumen; a sealant having an inner lumen; and a suture connected to at least one of the one or more suture attachment points of the intravascular anchor and passing through the inner lumen of the external vascular cap and through the inner lumen of the sealant to connect the intravascular anchor to the external vascular cap and the sealant. The suture may include a proximal suture portion and a distal suture portion, wherein the diameter of the distal suture portion is larger than the diameter of the inner lumen of the external vascular cap. The distal suture portion may create an interference fit to lock the external vascular cap above the perforation site, and each of the intravascular anchor, external vascular cap, sealant, and suture is formed of a bioabsorbable material.
[0015] The present invention also relates to a vascular closure device having one or more vascular caps formed of a flexible material, the sutures being braided sutures, a sealant being threaded onto the sutures at a location proximal to the vascular caps, the sealant, when activated, locking the vascular caps in place and coagulating the entry channel at the perforation site to provide immediate hemostasis, the vascular anchor having an elongated body, a raised keel located on the central axis of the elongated body and spanning the length of the elongated body (optionally including one or more suture attachment points), and the sealant being formed of polyethylene glycol (PEG).
[0016] The present invention also relates to an intravascular anchor for an intravascular closure device for immediate hemostasis at perforation sites in the vessel wall, the intravascular anchor comprising an elongated body including a flexible membrane for conforming to the vessel wall and a keel having one or more suture attachment points, wherein the keel is an elongated member centrally positioned along the central axis of the elongated body, and wherein the intravascular anchor comprises a bioabsorbable material selected from polyglycolic acid (PGA), poly-L-lactic acid (PLLA), polycaprolactone (PCL), poly-DL-lactic acid (PDLLA), polytrimethylene carbonate (PTMC), and polydioxanone (PPDO).
[0017] These and other objects and features of the invention will become more apparent from the following description and the appended claims, or may be learned by practicing the invention as set forth below. Attached Figure Description
[0018] A description of various aspects and features of the invention will be provided with reference to the accompanying drawings, which illustrate various representative embodiments of the invention. It should be understood that these drawings depict only typical embodiments of the invention and are therefore not intended to limit its scope.
[0019] Figures 1A to 1C A conveying system in which a closing device can be implemented is shown according to one embodiment.
[0020] Figure 1D An alternative conveying system for deploying a closure device according to the present invention is shown.
[0021] Figure 1E It shows Figure 1D A partial cross-sectional view of the alternative conveying system.
[0022] Figure 1F A schematic diagram of another alternative conveying system according to the present invention is shown.
[0023] Figure 2A and Figure 2B An example embodiment of the closing device is shown.
[0024] Figure 3A An embodiment of the cap of the closure device is shown.
[0025] Figure 3B It shows Figure 3A A cross-sectional view of the hat.
[0026] Figure 3C A layer with adhesive layer is shown. Figure 3A The hat.
[0027] Figure 3D It shows Figure 3C A cross-sectional view of the hat.
[0028] Figure 4 A cross-sectional view of a device for closing blood vessels is shown.
[0029] Figure 5 A cross-sectional view of a closure device applied to a blood vessel via an inlet tube is shown.
[0030] Figure 6A and Figure 6B A cross-sectional view of a closure device applied to a blood vessel via an inlet tube is shown.
[0031] Figures 7A to 7D An embodiment of an intravascular anchor for a closure device is shown.
[0032] Figure 7E and Figure 7F An alternative embodiment of the intravascular anchor for the closure device is shown.
[0033] Figure 7G and Figure 7H An alternative embodiment of the closure device is shown.
[0034] Figure 8A The lumen-facing side of an alternative embodiment of an intravascular anchor is shown.
[0035] Figure 8B It shows Figure 8A The side of the endovascular anchor facing the intima in an embodiment of the vascular anchor.
[0036] Figure 9A Another embodiment of an intravascular anchor is shown, with the lumen-facing side.
[0037] Figure 9B It shows Figure 9A The side of the endovascular anchor facing the intima in an embodiment of the vascular anchor.
[0038] Figure 10A Another embodiment of an intravascular anchor is shown, with the lumen-facing side.
[0039] Figure 10B It shows Figure 10A The side of the endovascular anchor facing the intima in an embodiment of the vascular anchor.
[0040] Figures 11A to 11D A method for delivering a closure device to an entry point on a blood vessel is shown.
[0041] Figure 12 An alternative embodiment of a conveyor system in which a closing device can be implemented is shown.
[0042] Figure 13A and Figure 13B It shows Figure 12Side view of the handle assembly of the delivery system.
[0043] Figure 13C It shows Figure 13A and Figure 13B A perspective view of the handle assembly.
[0044] Figure 13D It shows Figures 13A to 13C Top plan view of the handle assembly.
[0045] Figure 13E It shows Figures 13A to 13D A cross-sectional view of the handle assembly.
[0046] Figure 13F As shown Figure 13E An enlarged view of the handle assembly shown on page 13F.
[0047] Figure 14A An exploded view of the handle assembly of the conveying system is shown.
[0048] Figure 14B It shows Figures 12 to 14A Enlarged view of the chamber of the handle assembly.
[0049] Figure 14C It shows Figures 13A to 13E A cross-sectional view of the handle assembly, in which the implant component is removed from the handle assembly.
[0050] Figure 14D It shows Figure 14C A cross-sectional view of the slider of the implant component.
[0051] Figure 14E and Figure 14F It shows Figure 14D A perspective view of the slider positioned within the handle body.
[0052] Figure 15 It shows Figure 14A and Figure 14C Implant components.
[0053] Figure 16 It shows Figure 15 An exploded view of the implant components.
[0054] Figure 17A and Figure 17B An expander tube for implanting a closure device is shown.
[0055] Figure 18A and Figure 18B The conveyor sleeve of the conveyor system is shown.
[0056] Figure 19A and Figure 19BThe handle assembly is shown being inserted into and attached to the delivery sleeve.
[0057] Figure 19C It shows a partially deployed state. Figure 19A The conveying system.
[0058] Figure 19D It shows from such Figure 19B A close-up view of the implant assembly deployed in the delivery sheath section, as shown.
[0059] Figures 20A to 20B An expander tube inserted into a delivery sheath is shown according to the method of delivering a closure device to an entry point on a blood vessel.
[0060] Figure 21A The diagram illustrates a combination of a dilator tube and a delivery sheath inserted through a tissue channel, according to an entry point for delivering a closure device to a blood vessel.
[0061] Figure 21B A delivery sheath in a tissue conduit is shown according to a method of delivering a closure device to an entry point on a blood vessel.
[0062] Figures 21C to 21D A handle assembly connected to a delivery sheath is shown according to an entry point for delivering a closure device onto a blood vessel.
[0063] Figure 22 A partial deployment of a closure device is shown according to a method of delivering the closure device to an entry point on a blood vessel.
[0064] Figures 23A to 23C The deployment of the closure device and the removal of the handle assembly and delivery sheath are shown according to the method of delivering the closure device to the entry point on the blood vessel. Detailed Implementation
[0065] One or more specific embodiments of this disclosure will now be described. To provide a concise description of these embodiments, some features of actual embodiments may be described in the specification. It should be understood that in the development of any such actual embodiment, as in any engineering or design project, many specific decisions will be made for each embodiment to achieve the developer's specific goals, such as conforming to system-related and business-related constraints, which may vary from one embodiment to another. It should be further understood that such development efforts may be complex and time-consuming, but remain routine tasks of design, fabrication, and manufacturing for those skilled in the art who benefit from this disclosure.
[0066] One or more embodiments of this disclosure may generally relate to apparatus, systems, and methods for providing a closure device or implant configured to close an opening formed in tissue. The closure device or implant may be configured to provide immediate or substantially immediate hemostasis at the vascular puncture site and to deliver a hemostatic agent into the access channel to eliminate track effusion. The disclosed closure device or implant configuration prevents extravascular components from passing through the perforation site, and provides improved resistance to fracture and potential anti-embolism.
[0067] One or more embodiments of this disclosure may also generally relate to devices, systems, and methods for closing openings, wherein a portion of a closing device or closing implant is temporarily retained in the patient to close the opening and subsequently degrades, is absorbed, or is reabsorbed over a period of time.
[0068] While this disclosure describes specific embodiments of devices and systems for removing openings in closed tissue, and related methods, it should be understood that any systems, devices, and methods described herein may be adapted for other uses, including but not limited to closing existing or formed openings in tissue or body cavities in other locations of a patient's anatomy. Furthermore, elements described with respect to any embodiment depicted and / or described herein may be combined with elements described with respect to any other embodiment depicted and / or described herein.
[0069] Vascular closure delivery system
[0070] This disclosure relates to apparatus, systems, and methods for closing openings in blood vessels. For example, this disclosure includes an anchor, such as an intravascular anchor formed in one configuration of a bioabsorbable, bioresorbable, and / or biodegradable material. The anchor can be deployed through an opening defined in the vessel wall. The anchor can then be pulled proximally to bring it into distal contact with the luminal wall of the vessel. A closure element, such as an external vascular cap, can then be deployed to close the perforation.
[0071] In at least one embodiment, once deployed intravascularly, the anchor (and optionally, the cap) can degrade, be absorbed, or reabsorbed over a predetermined time period, such as between approximately 36 and 72 hours, in less than 48 hours, in less than approximately 36 hours, within a day, in less than an hour, or over some other time period as required. Rapid degradation, absorption, or reabsorption of one or more components of the device allows the anchor to remain in place after the closure device or closure implant has been deployed, eliminating the need for anchor removal. By leaving the anchor in place until its degradation, absorption, or reabsorption, damage that could occur by pulling the anchor through the closed perforation and / or the deployed closure element can be reduced or eliminated.
[0072] Furthermore, the degradation, absorption, or reabsorption time of the anchor can fall within the time frame of action of antithrombotic drugs used in conjunction with patient treatment. Therefore, the closure device or closure implant of this disclosure can reduce the risk of intra-arterial clot formation associated with closure of vascular perforation sites.
[0073] While references have been made to anchors remaining in the blood vessel and being degraded, absorbed, or reabsorbed by the patient's body, it should be understood that in other configurations, anchors may be deployed and subsequently removed once adequate closure of the perforation has occurred.
[0074] Now for reference Figures 1A to 1B This illustrates a closed device delivery system or closed implant delivery system 30 according to an example. Figures 1A to 1B As shown, the delivery system 30 may include a delivery sheath 40 having a nested set of actuators 50, 60, and 70 configured to cooperate in deploying a closure device or closure implant 100, which includes anchors 108 such as intravascular "legs" or anchors, and caps 102 such as caps 102 (see Figures 2 to 3). Figure 4 Closure elements, such as sealants (see Figures 2 to 10), Figure 4 The fluid-blocking component 104 (the terms fluid-blocking component and sealant will be used interchangeably herein) and the stitching element 106. For example, actuator 50 can be used to deploy anchor 108, actuator 60 can be used to deploy cap 102, and actuator 70 can be used to deploy fluid-blocking component 104. In at least one example, delivery sleeve 40 is configured to receive anchor 108, cap 102, and fluid-blocking component 104, and actuators 50, 60, and 70 are configured to deploy anchor 108, cap 102, and fluid-blocking component 104 from delivery sleeve 40, respectively. Reference will be made to... Figure 1B To discuss in more detail Figure 1A The exemplary components include a delivery sleeve 40, actuators 50, 60 and 70, anchor 108 and closing device 100.
[0075] Although the actuators 50, 60, and 70 are shown arranged coaxially within the conveyor sleeve 40, the actuators 50, 60, and 70 may be arranged non-coaxially within the conveyor sleeve 40, for example... Figure 1D and Figure 1E As shown, actuator 50 is arranged on one side of actuator 60. Additionally, returning to... Figures 1A to 1BWhile the following discussion provides one approach to deploying anchor 108, cap 102, and fluid blocking component 104 using specific actuators, those skilled in the art will understand that any combination of anchor 108, cap 102, and fluid blocking component 104 can be deployed in any order or sequence by one of actuators 50, 60, and 70. For example, while actuator 60 can deploy cap 102 and actuator 70 can deploy fluid blocking component 104, in other configurations, one of the actuators, such as actuator 70, may be eliminated, and actuator 60 may deploy cap 102, causing fluid blocking component 104 to advance toward cap 102, and deploying fluid blocking component 104 by a combination of distal and / or proximal movements relative to anchor 108. In other configurations, delivery system 30 may include two or more actuators, such as two or more actuators 50, 60, or 70, to deliver / deploy anchor 108, cap 102, and fluid blocking component 104. Other combinations of deployment functions may also be performed by other individual actuators or combinations of actuators. One or more cavities of one or more actuators 50, 60, or 70 may include one or more valves or seals 58, 68, and 78, and the delivery sheath 40 may also include one or more valves or seals 45 to prevent blood from flowing out of the delivery sheath 40 and the ends of actuators 50, 60, and 70.
[0076] Figure 1B An exploded view of the conveyor system 30 is shown. (As shown) Figure 1B As shown, the delivery sleeve 40 includes a housing 42 and a handle or grip portion 44. Each of the actuators 50, 60, and 70 includes shaft or housing portions 52, 62, and 72, handle or grip portions 54, 64, and 74, respectively, and a distal end that can mate with the anchor 108, the cap 102, and the fluid blocking member 104, respectively. For example, actuator 50 may include a notch 58 ( Figure 1AThe housing 42 receives the suture 106 and optionally a portion of the anchor 108. An internal cavity 46 is defined within the housing 42 and is configured to receive actuators 50, 60, and 70 in a manner that allows actuators 50, 60, and 70 to extend from and retract into the housing 42 from its distal end 48. Each actuator 50, 60, and 70 also includes internal cavities 56, 66, and 76, respectively, to allow translation of actuators 50, 60, and 70 (independently or in combination of two or more actuators) and the delivery sheath 40. The translational distance of actuators 50, 60, and 70 can be controlled by contact between adjacent handle or grip portions 44, 54, 64, and 74. For example, handle portion 44 may limit the distal movement of each handle portion 54, 64, and 74 associated with actuators 50, 60, and 70, while handle portion 74 may limit the distal movement of each handle portion 54 and 64, and handle portion 64 may limit the movement of handle portion 54. In this way, excessive translation of the respective actuators is limited, and anchor 108, cap 102, and fluid blocking component 104 can be effectively deployed to access and close tissue openings.
[0077] While reference has been made to a handle or grip portion that limits the translation of the actuator, it should be understood that other methods can be used to control translation. For example, complementary structures can be formed in the housing and internal cavities to limit translation. In another configuration, the handle or grip portion is combined into a single handle assembly with different actuation controllers, such as switches, knobs, sliders, etc., to allow independent or combined movement of one or more of the actuators 50, 60, and 70.
[0078] In another configuration, such as Figure 1C As shown, the inner cavity 46' may include a first portion 46A' configured to receive a shaft portion 54' of the actuator 50', while a second portion 46B' of the inner cavity 46' may be configured to receive the distal end 54A' of the shaft portion 54' having the inner cavity 56'. More specifically, the second portion 46B' of the inner cavity 46' may have a wider aspect ratio than the first portion 46A'. The aspect ratio of the first portion 46A' and the second portion 46B' may be their diameter or other cross-sectional profile generally transverse to the central axis C of the delivery sheath 40'. For ease of reference, the central axis C of the delivery sheath 40' will be referenced when describing the position and movement of other components described herein. In the illustrated embodiment, the inner cavity 46' may transition from the smaller diameter of the first portion 46A' to the second larger diameter of the second portion 46B' at a shoulder 46C'.
[0079] This configuration allows the actuator 50' to translate axially relative to the delivery sleeve 40' within a desired range of motion. Specifically, the handle portion 52' can translate within a second portion 46B' of the internal cavity 46' to advance the shaft portion 54' within the housing 42' relative to the handle or grip port 44', thereby moving the distal end 54A of the shaft portion 54' relative to the distal end 42A of the housing 42'. The interaction between the handle portion 52' and the shoulder portion 46C' helps ensure that the distal end 54A' does not extend beyond the desired position within the housing 42.
[0080] In the example shown, the first portion 46A' can also be configured to receive the anchor 108 and the cap 102 proximal to the distal end 54A' of the shaft portion 54'. Therefore, as the distal end 54A' of the shaft portion 54' advances toward the distal end 42A' of the housing 42', the distal end 54A' of the shaft portion 54' can engage the anchor 108 and / or the cap 102, allowing the anchor 108 and / or the cap 102 to move distally from the housing 42.
[0081] return Figure 1A Anchor 108 can be configured to move from a pre-deployment state having a pre-deployment width ratio to a deployment state having a deployment width ratio. The deployment width ratio can be greater than the pre-deployment width ratio. Anchor 108 can have any configuration that allows this. In the illustrated embodiment, anchor 108 is configured to rotate or be rotated between the pre-deployment state and the deployment state. In other embodiments, part or all of anchor 108 can be configured to unfold from a configuration having a pre-deployment width ratio to a deployment state having a larger width ratio. For example, one or more arms or wings can be configured to unfold and fold around multiple pivot points, hinges, active hinges, bent positions, preferred bent positions, combinations thereof, or modifications thereof.
[0082] like Figure 1A As shown, anchor 108 includes wing members 132, 134 that define the long axis 136 of anchor 108. Anchor 108 may also include one or more holes or eyelets 138 arranged along the length of anchor 108. The holes or eyelets 138 may be located at positions that cause anchor 108 to rotate when a force initially acting parallel to the long axis 136 is applied to the eyelet 138. This configuration allows anchor 108 to move from a state in which the long axis 136 is aligned with the central axis C to a state in which the long axis 136 is oriented more obliquely relative to the central axis C (e.g., substantially perpendicular to the central axis C).
[0083] This rotation can be achieved by applying a distal force to the anchor 108 to move the anchor 108 out of the housing 42, and then by applying a proximal force to the anchor 108 through the interaction between the stitch 106 and the eyelet 138. In at least one embodiment, the distal force applied to the anchor 108 can be provided by the actuator 50, while the proximal force can be applied by the stitch element 106. The anchor 108 can thus be used to position the delivery system 30 for deployment of the closure element 102.
[0084] In one embodiment, the closure element 102 may be configured to close an opening in the lumen of a blood vessel and at least partially block tissue channels leading from the outer surface of the tissue to the lumen. The shape of the closure element 102 may be configured to be received within an internal lumen 46 (or one of the other lumens of actuators 50, 60, 70). For example, the closure element 102 may conform to the shape of the internal lumen 46. In one embodiment, prior to deployment from the delivery sheath 40, the closure element 102 may be generally cylindrical, with portions of the closure element 102 at least partially wrapped around or bent toward a central portion, regardless of whether those peripheral portions are bent proximally, distally, or transversely to the deployment direction of the previously deployed anchor 108. Once deployed from the delivery sheath 40, at least a portion of the closure element 102 may be at least partially deformed to conform to any desired shape of the vessel wall to close the opening in the blood vessel and / or tissue channels leading to the luminal opening.
[0085] As shown, the suture element 106 can loop through the anchor 108, such that the suture element 106 passes through or near the closure element 102 and extends proximally into or beyond the handle portion 52 of the actuator 50'. In at least one embodiment, the free end of the suture element 106 passes through a separate portion or channel of the closure element 102. The suture element 106 can extend from the closure element 102 and enter the actuator 50 through the internal cavity 56.
[0086] Typically, the structure and components of the delivery system 30 may be formed from polymers, metals, alloys, combinations thereof, or modifications thereof. For example, by way of illustration only, the delivery sheath and actuator may be formed from a metal thiocyanate tube, a polymer tube, a composite tube with a multi-layer configuration, or other tubular structures that optionally include reinforcing members or braids. The outer diameter of the delivery sheath and actuator may range from about 6F to about 10F, from about 2 mm to about 4 mm, from about 2 mm to about 3.33 mm, or other dimensions known to those skilled in the art.
[0087] Vascular closure device
[0088] Figures 2A to 2BAn example of a closure device 100 is shown. In this particular configuration, the closure device 100 may be a fully bioresorbable vascular closure implant comprising an intravascular component and an extravascular component. The extravascular component may include an extravascular cap or lid 102 (hereinafter referred to as an "extravascular cap" or "cap") and a second extravascular component or fluid barrier 104, such as a bioresorbable sealant (see [link to original document]). Figures 4 to 6B These can also be collectively referred to as closure elements. Intravascular components may include intravascular prongs or anchors 108 and sutures 106, both of which may be bioresorbable. As mentioned above, in other configurations, intravascular prongs or anchors 108 may be temporarily deployed, wherein the extravascular components are fully bioresorbable (e.g., through degradation, absorption, and / or reabsorption).
[0089] The extravascular cap 102 may be made of a bioabsorbable material and have a sufficient size and geometry to prevent it from passing through the puncture entry site 18 on the surface of the blood vessel 10. The size and geometry of the extravascular cap 102 can significantly increase patient safety by preventing extravascular components from passing through the entry site 18 during or after deployment. The cap 102 may have a diameter from about 1 mm to about 10 mm, from about 3 mm to about 8 mm, from about 4 mm to about 5 mm, or other sizes based on the specific dimensions of the entry site 18, such that the cap 102 does not pass through the entry site 18.
[0090] The cap 102 may be low-profile and made of a biodegradable material with desired flexibility to conform to the patient’s access site anatomy (especially in vessels with significant calcification) and provide a more effective seal than rigid materials. The cap may be deployed through a small catheter into the tissue conduit 22 and placed on top of the vessel 10 as a primary external seal.
[0091] refer to Figures 2A to 3BThe figure illustrates one configuration of cap 102. As shown, cap 102 may have a generally disc-shaped form, but in other embodiments, the shape of cap 102 may be interrupted (e.g., star-shaped), which can give cap 102 increased flexibility to allow it to conform to a typically narrow inlet channel 22. Cap 102 may include a central portion 113 that may be raised relative to the surrounding surface 111 of cap 102. The central portion 113 may have a thickness of approximately 0.050 mm to approximately 5 mm, from approximately 0.10 mm to approximately 2 mm, from approximately 0.10 mm to approximately 0.5 mm, or various other thicknesses. Cap surface 111 may include a decompression slit 115, which can provide increased cap flexibility and conformity to the inlet channel 22 above the blood vessel 10. The decompression slit 115 may extend to the longitudinal axis of cap 102, and may be angled, bent, non-linear, or a combination or modification thereof. Alternatively, or in addition to the decompression incision 115, the decompression incision 115a may have a generally circular shape arranged around the intermediate portion 113, such as externally, surrounding, or encircling all or part of the intermediate portion 113. The decompression incision 115a may alter the flexibility of the surface 111 to improve conformity with the conduit and prevent entry into the blood vessel. The cap 102 may have a mass ranging from about 4.0 mg to about 10.0 mg (for a cap with a diameter of 4 mm to about 6 mm). With a lower total mass, less force is used to hold the cap 102 in place between the cap 102 and the frictional engagement between the suture 106. This results in a smaller overall system, making positioning within the patient easier while having a reduced overall impact on the patient's recovery.
[0092] Entering pipe 22 (see) Figures 4 to 6B The cap 102 is typically a size-constrained circle and is formed at an angle relative to the vessel wall. The cap 102 can be configured to slide down along the delivery system 30 through the inlet conduit 22 and deposit on top of the artery or vessel 10. The suture 106 can then be pulled to tension the cap 102 and the intravascular anchor 108 towards each other to seal the inlet site 18. The cap 102 may include an inner lumen 110 in a central portion 113 through which the suture 106 can pass to attach the suture 106 to the intravascular anchor 108. The lumen 110 may have a diameter ranging from approximately 0.010 (0.254 mm) to approximately 0.020 (0.508 mm), from approximately 0.012 (0.3048 mm) to approximately 0.017 (0.4318 mm), or from approximately 0.014 (0.3556 mm) to approximately 0.015 (0.381 mm).
[0093] The dimensions of the inner cavity 110 can be set to accommodate a suture 106 of a certain diameter. For example, as Figures 2A to 2BAs shown, when the stitches 106 surround the anchor 108, two tracks or portions of the stitches 106 can pass through the inner cavity 110 and proximally along the conveyor 30. Optionally, portions of the two stitches 106 can be woven together with the two stitch tails extending proximally from the cap 102. Alternatively, as... Figure 4 As shown, the suture 106 loops around itself and is woven within itself to increase the portion of the suture that interferes with or otherwise engages with the inner wall of the cavity 110, wherein a single track extends proximally along the conveying device 30. In another case, two sutures 106 may pass through... Figures 2A to 2B The elongated member 107 (e.g., another stitch portion or braided tubular member), shown by the dashed line, is woven into or woven together with the elongated member 107 to increase the size of the portion of the stitch 106 arranged within the cap 102. One or more elongated members 107 may optionally be inserted into the one or more stitches 106 to increase their size. In each case, i.e., two adjacent non-woven stitch tracks, two adjacent woven stitch tracks, woven stitches and tubular members, or the ends of the stitches woven into another portion of the stitch after interlacing through two or more holes in the anchor 108, a thicker stitch portion 112 is formed, which may interfere with the narrower inner cavity 110 relative to the thicker stitch portion 112 to secure the cap 102 in the desired position. The coarse stitch portion 112 may have a diameter ranging from about 0.020” (0.508 mm) to about 0.040” (1.016 mm), from about 0.024” (0.6096 mm) to about 0.034” (0.8636 mm), and from about 0.028” (0.7112 mm) to about 0.030” (0.762 mm).
[0094] The suture 106 may be made of a bioabsorbable material. For example, the suture 106 may be a multifilament or braided absorbable suture, for example, from... Those obtained. In one configuration, the suture is a braided 3-0 suture. High tensile strength may be advantageous for the suture, as it can maintain its integrity under applied forces ranging from approximately 3 lbf to approximately 6 lbf, although other sutures can accommodate applied forces ranging from approximately 1 lbf to approximately 16 lbf, from approximately 1 lbf to approximately 8 lbf, from approximately 2 lbf to approximately 6 lbf, from approximately 2.5 lbf to approximately 5 lbf, or approximately 2 lbf.
[0095] The cap 102 may initially be located on the proximal end of the suture 116, or on the end of the suture 106 whose diameter is no greater than the diameter of the lumen 110 of the cap 102. As the cap 102 advances along the suture 106 to the external vascular surface 20 at the arterial incision site, the coarse suture portion 112 causes interference that locks the cap 102 in place, thereby causing immediate dry closure.
[0096] Interference fits eliminate the need for knots to maintain suture closure. Using knots poses serious risks to the patient if the set tension on the suture becomes too tight. The suture can become stressed due to the patient walking or coughing, leading to over-tension and breakage. Interference fits can be advantageous because they are knotless and the flexibility of the cap adapts to the forces applied to the suture.
[0097] In addition to, or instead of, the interference fit between the cap 102 and the coarse suture portion 112, the cap may optionally include an adhesive applied to the side of the cap that contacts the extravascular tissue, such as... Figures 3C to 3D As illustrated in the embodiments. For example, cap 102 may include an adhesive layer 128 that binds to extravascular tissue as cap 102 advances toward anchor 108. The adhesive used for adhesive layer 128 may be a non-migratory adhesive because it will not flow through perforations when extravascular tissue is sandwiched between cap 102 and anchor 108. Such adhesives may include non-expanding adhesives, such as non-expanding polyethylene glycol (PEG), collagen, such as barnacle glue, cross-linked gelatin (non-biological), cyanoacrylate, polyurethane adhesives, or glues or adhesives, combinations and modifications thereof. More generally, adhesives may use cross-linking mechanisms that depend on chemical conjugation between reactive groups, free radical polymerization, redox reactions, biological or biochemical coupling.
[0098] Figures 4 to 6B An example of a second extravascular component or fluid-blocking component 104 is shown, which may be a sealant. The fluid-blocking component 104 may be an active biomaterial, such as polyethylene glycol (PEG), fibrin sealant, copolymers of glucosamine and N-acetylglucosamine, dextran (complex branched dextran (polysaccharide, polypeptide adhesive structure, adhesive protein containing L-3,4-dihydroxyphenylalanine (L-DOPA)), adhesive protein containing DOPA and phosphoserine, collagen, polyacrylic acid crosslinked with allyl sucrose or allyl pentaerythritol, polyacrylic acid crosslinked with divinyl glycol, acrylic resin polymers composed of methyl 2-cyanoacrylate units, or another fully bioabsorbable sealant-type material that may optionally be incorporated into a molded flexible matrix. This sealant material may be activated by fluids (e.g., blood or other fluids) present in the patient's tissue channels and may be protectively stored in the chamber of a sheath / actuator or delivery device until directly on top of the cap 102.
[0099] Once advanced to the desired location, the sealant 104 can be exposed to blood or fluid, for example, by dislodgement of the fluid barrier 104 and positioning it in direct contact with tissue, where it can react upon contact with blood and other fluids. This reaction causes the fluid barrier 104 to swell and absorb blood and other fluids, and to bind with the surrounding tissue and cap 102. The sealant acts as an adhesive and helps to “lock” the cap 102 in place on the blood vessel 10, and actively coagulates the entire inlet conduit 22. The chemical formulation, quantity, carrier matrix, and size of the fluid barrier 104 can be specifically selected to provide one or more locking functions in place of a sealing element (e.g., cap 102), thereby providing rapid-acting and leak-free dry closure and reducing tissue conduit leakage.
[0100] For example, the sealant can form a plug with a length of about 1 mm to about 10 mm and can optionally be trimmed to a certain length in the patient's body along with the suture after deployment, or the adhesive component can extend the full length of the tissue canal and be trimmed to fit the patient. When the fluid barrier component 104 is formed of a matrix, the matrix can have an area of about 0.012 square inches to about 0.12 square inches, about 0.12 square inches to 0.6 square inches, or about 0.6 square inches to 1.0 square inches. The matrix material can be thin and flexible, allowing it to be wound around the suture in a delivery system to fit within a tube for delivery to the implant site. This results in a fluid barrier component with a volume between about 0.004 and about 0.040 cubic inches, between about 0.0040 and about 0.100 cubic inches, or between about 0.100 and about 0.400 cubic inches, optionally including a matrix containing a sealant such as PEG or other biocompatible materials.
[0101] The fluid barrier component 104 can be deployed such that it is arranged on the suture 106. Therefore, the fluid barrier component 104 can be deployed in a flowable composition without a carrier matrix, or can be formed partially or having a carrier matrix. For example, the fluid barrier component 104 can be arranged around the suture in the form of a generally cylindrical component, can be incorporated into the suture itself, can be incorporated into a cap, and combinations thereof or modifications thereof. Because the sealant 104 is positioned proximally relative to the cap 102, the sealant 104 can actively condense into the inlet channels 22, and optionally actively condense all inlet channels 22 leading to the surface of the skin 16.
[0102] like Figures 4 to 6BAs shown, the sealant 104 may have a conical configuration when deployed, although in other embodiments the sealant 104 may have a continuous or uniform thickness along its length. The extravascular cap 102 may displace tissue at the entry site 18 because the cap 102 may be larger than the arterial incision. The sealant 104 may also fill the space created by the displaced tissue. The sealant 104 may be formed of a material having the property of expanding from its original size when it comes into contact with bodily fluids, thereby resulting in it effectively covering and reinforcing the seal formed by the cap 102. The sealant 104 may expand from its original size by approximately 1 to approximately 6 times, from approximately 2 to approximately 4 times, or from approximately 2.5 to approximately 3.5 times. Advantageously, the sealant may optionally expand upward along the entry channel 22 as close as possible to the skin 16 to reduce any bleeding.
[0103] When the sealant has a predetermined conical or tapered shape, sealant 104 may be formed as a separate sealant component with an opening through a center or other location to allow sealant 104 to pass through suture 106. More generally, the suture may pass through one or more points, through or around the sealant. The sealant component may be a foam matrix or other shaped substrate into which a biocompatible material may be injected and then shaped to the desired form, such as PEG. Sealant 104 may be a combination of two or more components that may be loaded into one of actuators 50, 60, or 70 and then simultaneously activated by pressing a handle or grip portion to expose sealant 104 to bodily fluids. The two or more components may include one or more flowable components, with or without a pre-shaped or biased matrix.
[0104] In other embodiments, the sealant 104 and the cap 102 may be deployed together as if they were a single component. The cap 102 may cover the entry point 18, and the sealant 104 may be activated on top of and above the cap 102 to seal the entry conduit 22.
[0105] In other embodiments, such as Figure 1FAs schematically shown (where actuator 50, anchor 108, and cap 102 are omitted for ease of explanation), a fluid-blocking component or sealant 104 may be stored in a chamber 103 at the proximal end of the delivery system. The fluid-blocking component or sealant 104 may be stored in a generally planar or flat sheet form, optionally biased to this form, and advanced to the cap 102 via a funnel 105 or other proximal deployment port that allows the planar or flat sheet form to be curled, folded, or otherwise altered to a form capable of advancing toward the cap 102. In one configuration, actuator 70 can be used to advance a fluid-blocking component or sealant 104 from a chamber (arrow A) along actuator 60 to deploy the sealant 104 from within actuator 60, for example, when actuator 70 advances distally (arrow B), or when actuator 60 is partially retracted proximally from engagement with cap 102 after tissue has been clamped between cap 102 and anchor, by movement of another actuator or structure, or a combination or modification thereof. This movement exposes the fluid-blocking component or sealant 104 to blood or other fluids, causing the fluid-blocking component or sealant 104 to expand.
[0106] When a coagulant or sealant is introduced, there is a risk of introducing embolic material into the blood vessel 10, which can lead to clots and threaten the limb. Emergency surgery may be required to remove the foreign body. This risk is mitigated by the configuration of the closure device 100, which prevents the extravascular fluid blocking component or sealant 104 from entering the blood vessel 10 by using a cap 102 to initially cover the entry site 18.
[0107] The combination of the low-profile cap component and the active sealant material on top makes this extravascular implant unique and distinguishes this design from other closure devices. The low-profile cap component includes a stable, biodegradable, absorbable, or reabsorbable material that does not swell or bind strongly to the tissue.
[0108] Now go to Figures 7A to 7H The closure device 100 may include an intravascular anchor 108, such as a transplanted anchor. The intravascular anchor 108 may include one or more of the following elements: 1) a large surface area of an elongated shape, or referred to as an elongated member 117; 2) a central keel 120 that provides suture attachment and overall rigidity; 3) a flexible portion or membrane 122 that conforms to the vessel wall; 5) a hole, eyelet, or other structure 118 that provides suture attachment to an external vessel component (e.g., cap 102) of the closure device 100; and 6) a flexible edge 126 of the flexible portion or membrane that allows storage in a cylindrical state, thereby allowing delivery of the closure device 100 to the vessel 10. The anchor 108 may be formed from a plurality of interconnected sub-components or formed as a single integral component, wherein one or more of the identified elements are formed as a single component, for example by casting or by machining of the starting workpiece.
[0109] The intravascular anchor 108 (also referred to as the "anchor") may be formed of a bioabsorbable material while possessing flexibility that allows the anchor 108 to be wound into a smaller profile within a delivery sheath (such as delivery sheath 40). This allows for the unfolding of a larger sealing surface once disengaged from the delivery tube. The intravascular anchor 108 is attached to the suture 106 using a pattern that distributes tensile loads more broadly across the width of the anchor 108 to prevent breakage due to high concentration forces during device deployment.
[0110] The intravascular anchor 108 may have a curved profile to better conform to the curvature of the vessel wall. The anchor 108 may also have an enlarged central portion or a keel 120. The keel 120 helps reinforce the seal formed by the closure device 100 above the entry point 18 and provides a suture attachment point. The rigidity of the keel 120 provides mechanical leverage and a stable position for the anchor 108 to advance and eject from the delivery sheath 40. The keel 120 may have a thickness of approximately 0.5 mm to approximately 0.8 mm, approximately 0.6 mm to approximately 0.9 mm, approximately 0.7 mm to approximately 1.0 mm, or other thicknesses, to provide the desired suture attachment location.
[0111] Surrounding the keel 120 is an elongated member 117. The material forming the elongated member 117 may be the same as the keel 120, such as a bioabsorbable material, wherein material A has a hardness ranging from about 50 Shore hardness to about 100 Shore hardness, from about 80 Shore hardness to about 90 Shore hardness, or a hardness selected based on the closed position. The elongated member 117 may have a flexible segment that is thinner than the keel 120, which can conform to the curved vessel wall 14. This flexibility may also allow the anchor 108 to conform to the unique calcification accumulation in the vessel 10. The elongated member 117 may have an elliptical or oval shape, with a minor axis dimension ranging from about 2.0 mm to about 10.0 mm, from about 3.0 mm to about 5.0 mm, or about 4 mm, while the major axis may range from about 4.0 mm to about 12.0 mm, from about 6.0 mm to about 8.0 mm, or about 6.0 mm. It should be understood that the configuration of anchors, and more generally, the configuration of closure devices or implants, can vary based on the specific opening to be closed, such that adjustable sizes can accommodate openings typically 5-8F or openings greater than 8F but less than 5F.
[0112] The ridge or keel 120 may extend along the length of the central axis of the elongated member 117 and may provide rigidity at locations where the seam 106 can be attached. The seam 106 may be attached via seam attachment points or holes 118 in the keel 120. One or more holes 118 may provide points through which the seam 106 can pass to attach the anchor 108 to the cap 102 and the sealant 104. The holes 118 may be spaced evenly or non-uniformly along the length of the keel 120. The spacing of the holes 118 helps to distribute tensile loads over the desired length of the anchor 108, such as all or part of the length of the anchor 108, and prevents the anchor 108 from breaking under load. Figures 7A to 7H In the embodiment shown, the free distal ends of the suture 106 can pass through each of the outermost holes 118a, and then both can pass through the intermediate hole 118b and upward through the entry portion 18, and be woven back onto the suture 106 to form the coarse suture portion 112.
[0113] Anchor 108 may be injection molded, cast, stamped, machined, a combination thereof, or a modification thereof, and depending on the desired degree of strength, stiffness, and absorbability, may include one or more bioabsorbable materials, bioabsorbable polymers, or bioabsorbable elastomers. The anchor 108 structure may be formed from a homogeneous mixture of materials, wherein flexibility is tuned through a combination of geometry and material formulation. A second adhesive material may be attached or bonded to the bottom surface of anchor 108 to increase adhesion strength and improve sealing performance to the blood vessel. The anchor provides a safe means for the sealant to interact directly with vascular tissue without the risk of embolization into the vascular lumen because it is attached to anchor 108. Bioabsorbable materials may include, for example, but not limited to, polyglycolic acid (PGA), polylactic acid (PLA), poly-L-lactic acid (PLLA), polycaprolactone (PCL), poly-DL-lactic acid (PDLLA), polytrimethylene carbonate (PTMC), poly(p-dioxanone) (PPDO), combinations thereof, and / or modifications thereof. More generally, the material forming the anchor 108 may have a hardness ranging from about 80 Shore hardness to about 90 Shore hardness. Alternatively, when the anchor 108 is temporarily deployed, the anchor may be formed of a non-bioabsorbable material, such as polyvinyl chloride (PVC), polyetheretherketone (PEEK), polytetrafluoroethylene (PTFE), nylon, silicone, urethane, thermoplastic elastomers (e.g., polyether block amide (PEBAX), polyethylene terephthalate (PET)), fluoropolymers, or biocompatible materials, combinations therewith, and / or modifications thereof.
[0114] The anchor 108 may have a mass ranging from approximately 4 mg to 8 mg (for a 4 mm × 6 mm ellipse), from approximately 8 mg to approximately 16 mg (for a 5 mm × 7 mm ellipse), or from approximately 15 mg to 30 mg (for an 8 × 10 mm ellipse). Due to the smaller total mass, a smaller force is used to hold the anchor 108 in place between the cap 102 and the suture 106 in a proper position through frictional engagement. This results in a smaller overall system, making positioning within the patient easier while having a reduced overall impact on the patient's recovery.
[0115] Figure 8A and Figure 8B Another example embodiment of the intravascular anchor 108 is shown. Figures 8A to 8B In the middle, the anchor 108 includes a side 127 facing the inner cavity. Figure 8A ) and the side facing the endometrium 129 ( Figure 8B Anchor 108 may include an elongated body 117 having a flexible member or membrane 122, and a keel 120 positioned at the central axis of the elongated body 117 and spanning the length of the elongated body 117, which can provide sufficient rigidity for attaching the intravascular anchor 108 to the extravascular element of the closure device 100 via suture 106 (e.g., cap 102).
[0116] The keel 120 may be raised relative to the inner cavity side of the anchor 108, which helps maintain the position of the anchor 108 on the vessel wall 114. The inner membrane side of the anchor 108 may include a plurality of ribs 124 radiating outward from the keel 120 to raised edges 126 forming the periphery of the elongated body 117. The raised elements of the ribs 124 and the raised edges 126 provide encapsulation of localized plaques on the vessel wall 114. The stiffness of the raised edges 126 of the anchor 108 may be related to the stiffness and / or pattern, number, and / or thickness of the ribs 124 radiating from the keel 120. The width and taper of the ribs 124 may vary to affect the compliance or stiffness of the edges 126 of the anchor 108.
[0117] Figures 9A to 9B Another embodiment of anchor 208 is shown. Anchor 208 may include an elongated body 217 having a flexible member or membrane 222, and a centrally located raised keel 220 spanning the length of the elongated body 217. The elongated shape of anchor 208 is modified to maximize the surface area of anchor 208. In this illustration, the number of ribs 224 is reduced, which can increase compliance with the vascular lumen wall 14. Anchor 208 may also have raised edges 226 extending around the periphery of the elongated body 117. One or more holes 218 in the keel 220 provide points through which sutures 106 can pass to attach anchor 208 to the vascular external component of closure device 100.
[0118] Figures 10A to 10B Another embodiment of the anchor 308 is shown. The anchor 308 may include an elongated body 317 having a flexible membrane and a raised keel 320 located along and spanning the length of the central axis of the elongated body 317. The keel 320 may include one or more holes 318 through which a suture 106 may pass. In this embodiment, ribs (124, 224) are omitted to allow for maximum flexibility of the anchor 308. A raised edge 326 extending peripherally on the inner membrane side of the anchor 308 provides the necessary structural integrity to maintain the shape of the anchor 308 when positioned on the inner cavity wall 14.
[0119] Method of inserting the closing device
[0120] Now for reference Figure 11A This illustrates one step in the process of deploying anchor 108. For example... Figure 11A As shown, the delivery sheath 40 can be positioned to move the distal end of the outer shell 42 through the access conduit 22 defined in the tissue 72 and to the vicinity of the lumen 12 (and particularly the puncture or access site 18 defined in the lumen wall 14). The distal end of the delivery sheath 40 advances into the lumen 12 until it reaches the proximal blood outlet port 49 of the lumen, which is located from the reflux or blood-marked lumen formed in the wall of the delivery sheath 40 or by separate reflux vessels formed inside or outside the delivery sheath 40. Figure 1A Visually observe pulsating blood.
[0121] Once blood flow is observed, it can be done as described above (and as...) Figure 11B (As shown) Actuator 50 is manipulated to cause anchor 108 to be pushed out of the distal end 42A of housing 42. Alternatively, actuator 60 may actuate a closing element or cap 102, which may in turn push anchor 108 distally relative to housing 42, thereby deploying anchor 108 from the distal end 42A of housing 42. In this case, actuator 50 may optionally be omitted.
[0122] In one embodiment, once deployed, the anchor 108 can be rotated from a first orientation to a second orientation, in which the main axis 136 of the anchor 108 is at a small angle or substantially parallel to the housing 42 and substantially perpendicular to the inner cavity wall 14, such as... Figure 11A As shown, in the second orientation, the main shaft 136 of the anchor 108 is substantially parallel to the inner cavity 12 and forms a larger angle or is substantially perpendicular to the conveying sleeve 40, such as... Figure 11B As shown.
[0123] In particular, such as Figure 11BAs shown, once the anchor 108 is pushed from the distal end 42A of the housing 42, the anchor 108 can be rotated or rotated to a second orientation, for example by tension applied to the anchor 108 by the stitching element 106 via the central or intermediate hole 118B. The anchor 108 can then be pulled in the proximal direction to secure it against the distal surface 14A of the inner cavity wall 14, as... Figure 11B As shown by the dashed line in the image. Although in Figure 11A and Figure 11B The diagram shows suture 106 extending proximally within the cavity of actuator 50, but this is not the case when the actuator is not coaxial, for example... Figure 15 and Figure 16 As shown, the suture 106 does not need to extend within the cavity of the actuator 50, and the actuator 50 does not need to include a cavity. The suture 106 can extend within any cavity of the delivery system 30, for example... Figure 16 The solid and dashed lines of the suture 106 are shown in the diagram.
[0124] With the anchor 108 deployed and positioned against the inner wall 14 and the delivery sheath 40 partially retracted into the inlet conduit 22, the distal actuator 60 can then deploy the cap 102 proximal to the perforation 18 between the inner wall 14 and the tissue 72 through which the conduit 22 passes. Specifically, as Figure 11C As shown, actuator 60 can advance distally, pull delivery sheath 40 proximally, and / or combinations of such movements can be used to move cap 102 distally beyond housing 42 and into contact with the proximal side of inner wall 14 of adjacent perforation 18 or the lateral side of vascular bundle 14B. Inner wall 14 is positioned between anchor 108 and cap 102, wherein cap 102 is positioned on the lateral side of vascular bundle at entry point 18 and is “locked” in place due to interference fit created by coarse stitch portion 112. Thus, cap 102 can be positioned to reduce or stop fluid outflow from conduit 22 by covering perforation 18 and / or blocking conduit 22.
[0125] To detect a decrease or cessation of flow, interns can observe the blood flow from port 49 (…). Figure 1A The blood flow is monitored, and the extent of hemostasis is determined. From blood outlet port 49 ( Figure 1AThe degree of bleeding can indicate that hemostasis has not been adequately achieved and instruct the intern to continue positioning the cap 102 against the tissue to provide improved hemostasis. Alternatively, blood flow can be observed by keeping one or more valves or seals 58, 68, 78 of actuators 50, 60, or 70, or one or more valves or seals 45 of delivery sheath 40 open to allow blood to flow from the end of one or more actuators 50, 60, or 70, or delivery sheath 40. For example, by way of an example of a particular configuration, actuator 60 may include an enlarged portion that keeps the valve or seal 45 of delivery sheath 40 open, such that blood exits from the end of the lumen before hemostasis is achieved. As from blood outlet port 49 ( Figure 1A Similar to the blood flow from one or more actuators 50, 60, or 70, or the end of the delivery sheath 40, the degree of blood flow can indicate that hemostasis has not been adequately achieved and instruct the intern to continue positioning the cap 102 against the tissue to provide improved hemostasis. Retracting the enlarged portion away from the one or more valves or seals, or advancing the enlarged portion through the one or more valves or seals, allows the valves or seals to close after advancing the cap 102 toward the anchor 108, to improve hemostasis and reduce blood flow.
[0126] Back Figure 11C Advancing the cap 102 toward the anchor 108 helps stabilize the tissue around the perforation 18 to facilitate the closure of the perforation 18. Specifically, once the anchor 108 and cap 102 are deployed, tension can be applied to the suture 106 to secure the anchor 108 against the distal side 14A of the inner wall 14 as the actuator 60 advances the cap 102 distally. In one embodiment, a suture lock (not shown) may be used to help maintain tension in the suture element 106. The combined forces applied to the inner wall 14 by the anchor 108 and cap 102 provide compressive force on the tissue near the perforation 18, i.e., clamping the tissue between the anchor 108 and cap 102. The tension applied to the suture can range from 1 lbf to approximately 16 lbf, from approximately 1 lbf to approximately 8 lbf, from approximately 2 lbf to approximately 6 lbf, or approximately 2.5 lbf. Because the anchor 108 is formed of an elastic, compliant material, and the cap 102 can be formed of an elastomeric material (e.g., a bioabsorbable polymer, a bioabsorbable elastomer, etc.), these properties allow the anchor 108 and cap 102 to adapt to applied forces without breaking. The suture 106 may also include a visual indicator to show the user that the cap 102 has reached the appropriate depth, i.e., that it has reached the artery. If too much force is applied, this could cause the suture to break; however, due to the lack of a knot or other static element holding the cap 102 in place, the cap 102 and anchor 108 will not be over-tensioned. Because of this feature, the user does not need to worry about the degree of force applied.
[0127] The placement of the cap 102 also pushes the tissue 72 in the transverse direction relative to the axis of the conduit 22. This increases the space for subsequent delivery of the sealant 104, and thus increases the surface area of the inner wall 14 and the cap 102 that can receive the sealant 104. By doing so, the effectiveness of the inlet closure is enhanced.
[0128] Alternatively, in one configuration, when the actuator 60 can deploy both the anchor 108 and the cap 102, the actuator 60 can maintain continuous contact with the cap 102 throughout the deployment process. This configuration allows the deployment of the anchor 108 and / or the cap 102 by advancing the actuator 60 in a single direction. The deployment of the anchor 108 and the cap 102 is facilitated by using the unidirectional movement of the actuator 60, and by utilizing a single actuator, the delivery system can be used quickly and easily to deploy the anchor 108 and / or the cap 102, as well as the sealant 104.
[0129] Alternatively, in one configuration, when actuator 60 can both deploy cap 102 and advance sealant 104 toward cap 102, distal movement of actuator 60 advances sealant 104 toward cap 102, and subsequent proximal movement releases sealant 104 from actuator 60. In this configuration, actuator 70 may optionally be omitted.
[0130] Returning to the illustrated configuration, once cap 102 is placed, sealant 104 can be deployed from delivery sleeve 40 by retracting delivery sleeve 40 proximally (and optionally actuator 60) and advancing actuator 70 distally, or by one or more combinations of such movements, to advance or release sealant 104 from housing 42 and contact the proximal side 14B of inner cavity wall 14 and cap 102. When delivery sleeve 40 moves proximally or is removed, and / or when actuator 60 moves proximally or is retracted, sealant 104 is exposed to bodily fluids to activate sealant 104, such as... Figure 11D As shown. The activated sealant 104 can be used as an adhesive to hold the cap 102 in place, and to enhance the hemostatic effect of the cap 102 by preventing leakage and condensation into the conduit 22. It is advantageous to place the sealant as close to the skin surface as possible to reduce any potential bleeding.
[0131] When the sealant is activated, for example, within approximately 0.25 to 5 minutes, approximately 0.5 to 4 minutes, approximately 1 to 3 minutes, approximately 0.25 to 1 minute, or approximately 0.25 to 0.75 minutes, the intern can observe blood exiting from port 49. Figure 1AThe cap 102, based on the force applied to seal the entry site 18, can seal or substantially seal the entry site 18, resulting in the sealant 104 being used to limit tissue leakage around the cap 102 and from the tissue conduit 22, and providing secondary fixation of the cap 102 relative to the suture 106 and the entry site 18. In other words, the initial closure of the entry site 18 can be achieved by the seal provided by the anchor and the cap, while the sealant 104 provides a secondary seal and / or prevents leakage from the conduit. However, if there is blood flow from the blood outlet port 49 ( Figure 1A If the flow of blood is not continuous, the physician can manipulate the actuators and anchors to tighten the cap 102 onto the suture 106, or optionally wait for the sealant 104 to be fully activated to reduce or eliminate blood flow to the physician's preferred level. More generally, using the combination of the cap 102 and the sealant 108, a dry closure can be achieved within seconds of the sealant being activated. The user can also compress the area with gauze to squeeze out any blood and then check for hemostasis. While illustrative times for hemostasis are provided, the time to hemostasis can be affected by the anticoagulant medication administered to the patient. With the combination of the cap and the proximal sealant, hemostasis can be achieved faster than with the sealant alone.
[0132] Whether complete or substantially complete hemostasis occurs from cap 102 or from the combination of cap 102 and sealant 104, after hemostasis is achieved, the suture 106 can be trimmed by pushing downwards on skin 16 while tensioning the suture 106 and using a suture trimming device (not shown) (e.g., a scalpel or other suture trimming device) to trim the suture as close to the skin as possible. Once the skin is released, the suture will be well below the surface of the skin, as... Figure 11D As shown.
[0133] While reference is made to anchors 108 (208, 308) that remain in the blood vessel and are degraded, absorbed, or reabsorbed by the patient's body, it should be understood that in other configurations, anchors 108 may be deployed and subsequently removed once the perforation has been adequately closed. In this case, anchor 108 is "temporarily" deployed, and other parts of the closing element, such as those with adhesive layer 128 (see [link to relevant documentation]), are closed. Figure 3C and Figure 3DThe cap 102 and the fluid-blocking component 104 described herein are used to close the entry site after the anchor 108 is removed. The cap 102, having an adhesive layer 128, may or may not cooperate with and lock onto the suture 106, which is optionally attached to the anchor 108. The cap 102 is held in place against the vessel wall 14 by the adhesive layer 128 and the optional fluid-blocking component 104, wherein the fluid-blocking component 104 reduces or eliminates any leakage from tissue channels. In this alternative configuration, delivery of the temporary anchor, cap, and sealant can be performed using the delivery system and apparatus described herein, while accommodating the removal of the anchor 108 by pulling the suture 106 proximally or by removing the anchor 108 using another anchor actuator. The anchor 108 may optionally pass through the inner cavity 110 of the cap 102, wherein the body of the cap has sufficient elasticity to return to a closed state, thereby closing the entry site. Alternatively, the anchor 108 can be withdrawn from one side of the cap 102, wherein the cap 102 has sufficient elasticity to temporarily deform, thereby returning to a sealed state against the outer side of the blood vessel wall.
[0134] Handle assembly vascular closure delivery system
[0135] Figures 12 to 23B A conveying system and method for inserting a closure device of the type described above are illustrated. The conveying system 430 may include a handle assembly 400 and a conveying sleeve 440. The handle assembly 400 may be configured to selectively attach to the conveying sleeve 440 (similar to the conveying sleeve 40). Once attached to the conveying sleeve 440, the handle assembly 400 can be used to insert a closure device, such as closure device 100.
[0136] like Figures 12 to 13E As shown, the handle assembly 400 may include a handle body 402 having a proximal end 404 and a distal end 406, an actuator such as a slider 450, and an elongated opening 408 configured to provide a track for the slider 450. The slider 450 may be configured to slide along the elongated opening 408 when engaged by a user and to be selectively locked in place by a locking assembly 425. This engagement may deploy a closure device 100. The handle assembly 400 may also include a second slider 460 (see...). Figure 13A The second slider 450 is configured in a second elongated opening 412 on the handle body 402. Engagement of the second slider 460 deploys the anchor 108, and engagement of the second slider 460 deploys the cap 102.
[0137] In other embodiments, the handle assembly 400 may have only one actuator element, such as a slider 450, which can subsequently deploy the anchor 108 and cap 102 upon engagement, without requiring a second slider.
[0138] In some embodiments, such as the one shown in the accompanying drawings, the handle body 402 may include one or more textured portions 414 to improve user grip on the handle assembly 400. The handle assembly 400 may also include a connecting member 416 located at the distal end 406 of the handle body 402 and configured to selectively attach to and be removable from the delivery sleeve 440. The connecting member 416 may be configured to attach to a sleeve bushing 418 of the delivery sleeve 440. Figures 13A to 13F As shown, the connecting member 416 includes a set of locking members 420 having hook-shaped ends 422. The locking members 420 can be configured to selectively attach to the sheath bushing 418 of the conveyor sheath 440, which attaches the handle assembly 400 to the conveyor sheath 440 to form the conveyor system 430.
[0139] The handle assembly 400 may also include a release button 424 that releases the suture 106 once the closure device 100 is placed in the desired position. Engagement of the release button 424 releases the delivery system 430 from the implanted closure device 100. The release button 424 may include an engagement element, such as a release button flap 419. The release button flap 419 may engage within a release recess 407 and may be configured to slide within the length of the recess 407 to release the suture 106 of the closure device 100 from the handle assembly 400. In other embodiments, the functionality of the release button 424 may be incorporated into one or more actuator elements, such as slider 450 and / or sub-slider 460.
[0140] Figure 13E A cross-sectional view of the handle assembly 400 is shown. As shown, the slider 450 may include a first slider portion 450a and a second slider portion 450b. Slider portions 450a and 450b may be selectively connected together via interlocking ends 466a and 466b. A proximal locking assembly 421 may engage the slider 450 to “lock” the slider 450 at the proximal end 404 of the handle assembly 400. For example, complementary structures 421a and 451a on the sliding portion 450a of the proximal locking assembly 421 and the slider 450 may engage to restrict movement of the slider 450, while pressing the proximal locking assembly 421 disengages or separates the complementary structures 421a and 451a to allow the slider 450 to move distally. Slider portions 450a and 450b, interlocking ends 466a and 466b, and the proximal locking assembly 421 may be made of an elastic material, such as flexible plastic, to allow the components to bend when pressed by a user. For example, a user can press the proximal locking assembly 421 to release the slider 450 and allow the slider 450 to slide along the elongated groove 408. The proximal locking assembly 421 may be formed together with the handle body 402, for example, having a movable hinge connection with the handle body 402, or it may be a separate mechanism that is connected to or mounted to the handle body 402.
[0141] Figure 14A and Figure 14C An exploded view of the handle assembly 400 is shown. The handle body 402 may include a first side 403 and a second side 405, which, when assembled together, form an inner cavity 428 of the handle body 402. The first side 403 and the second side 405 may be assembled together to form the handle body 402 using fasteners, such as screws 409 inserted into corresponding holes 411.
[0142] like Figure 13F and Figure 14B As shown, the handle body 402 may also accommodate a chamber assembly 427 having a chamber body 427a and a chamber cap 427b, which may be disposed at the distal end 406 of the handle body 402. Although the chamber assembly 427 is shown as two parts, it will be understood that the chamber assembly 427 may be formed using fewer or more parts to provide the functionality described herein. The chamber assembly 427 may also be formed separately from the handle body 402, as shown, but in other embodiments, the chamber assembly 427 may be integrally formed within the handle body 402. The chamber assembly 427, particularly the chamber body 427, may be aligned with the lumen 428 and the distal opening 436 to form a channel 437 through which the implant assembly 426 deploys the closure device 100.
[0143] The chamber assembly 427 may include a chamber body 427a having a nozzle 429 and a nozzle ring 439. The nozzle 429 and ring 439 may be shaped to engage with the delivery sheath 440 and form a fluid-impermeable seal. An implant assembly 426 may be deployed from a cavity 428 through a channel 437 and then exit the nozzle 429 of the chamber assembly 427, for example, from the chamber body 427a, into the delivery sheath 440. In some embodiments, the chamber assembly 427 may include a valve 431. The valve 431 may be a one-way valve that prevents fluid from entering the cavity 428 of the handle body 402. The valve 431 may be located within a valve notch 472 at the proximal end of the chamber body 427a. The chamber body 427a may also include a platform 433. The chamber assembly 427, as shown, includes a chamber cap 427b. The chamber cap 427b may be located on top of the chamber 427 in the distal end 406 of the handle body 402. The chamber cap 427b helps form the channel 437 and may include one or more positioning elements 435 that hold the chamber cap 427b in the correct orientation and position within the handle body 402. When connected or coupled together, the chamber body 427a and the chamber cap 427b form a cavity 449 to receive a closure device, such as... Figure 13F As shown. Cavity 449 is connected to and forms part of inner cavity 428.
[0144] Implant assembly 426 is included within handle body 402. Implant assembly 426 accommodates closure device 100 and other elements required for placement of closure device 100. Implant assembly 426 may be configured to be positioned within a cavity 428 of handle body 402. Cavity 428 may extend along longitudinal axis 432 from a proximal opening 434 at proximal end 404 and terminate at a distal opening 436 on distal end 406 of handle body 402. Implant assembly 426 may be located within cavity 428 such that it is in mechanical communication with elements of handle body (i.e., slider 450 and sub-slider 460).
[0145] exist Figure 14A , Figures 14C to 14F , Figure 15 and Figure 16 The implant assembly 426, shown in detail, includes a closure device (e.g., closure device 100), a support tube 442, a slider 438, and a stop 444. The slider 438 may include a slider body 446 having a protrusion 448 that provides a mechanical interface between a slider 450 on the outer side of the handle body 402 and a slider body 446 on the implant assembly 426 located within the cavity 428 of the handle body 402. The slider 438 may also include a groove 447a configured to receive nested elements of the implant assembly 426 (support tube 442, closure device 100, packing tube 454, and push suture 452). The slider 438 may also include a suture groove 447b that allows mechanical communication between the implant assembly and the handle body 402 to facilitate the release of the suture 106 from the implant assembly 426.
[0146] The stop 444 may include a stop bend 466 configured to engage with an internal locking mechanism 423. As the stop 444 moves in the distal direction toward the distal end 406 of the handle body 402, it passes the internal locking assembly 423. Once past the internal locking assembly 423, the stop bend 466 engages the internal locking assembly 423, thereby preventing movement of the stop 444 in the proximal direction. The stop 444 prevents closure elements (e.g., fluid blocking member 104) from flowing back into the handle assembly 400. The internal locking mechanism 423 may be formed together with the handle body 402, for example, having a hinged connection to the handle body 402, or it may be a separate mechanism connected to or mounted to the handle body 402.
[0147] Figure 14D and Figure 14EA detailed view of the slider 438 of the implant assembly 426 is shown. As described above, the slider 438 may include one or more structures configured to engage with external elements of the handle body 402 to control the insertion and placement of the closure device 100 and the disengagement of the closure device 100 from the delivery system 430. A suture groove 447b of the slider 438 may receive a pin 417 located within an aperture 415.
[0148] like Figure 14F As shown, the suture 106 can loop around the pin 417 during assembly, and during insertion of the closure device 100, the frictional engagement of the suture 106 between the pin and the suture groove 447b retains the suture 106 within the slider 438. After the closure device 100 is deployed into the blood vessel, the delivery system 430 is disengaged from the closure device 100 by releasing the suture 106 from the slider 438. The release button 424 slides proximally toward the pin 417, causing the release button flap 419 to push the pin 417 into the hole 415. When the pin 417 is pushed into the hole 415, the suture 106 is released from the pin 417, effectively releasing the suture 106 and the closure device 100 from the delivery system 430.
[0149] The support tube 442 may include a suture 106 that can pass through it. The support tube 442 may also include a push suture 452 and a packing tube 454. The distal tip 456 of the push suture 452 may have a forked or forked shape to help push the closure device 100 out of the delivery system 430, while the proximal end includes a push suture bend 477 mounted to the slider portion 450a, so that the push suture 452 can be moved by the movement of the slider portion 450a. After positioning the anchor 108, the cap 102 of the closure device 100 can be packed with the packing tube 454. The stop 444 prevents the implant assembly 426 from sliding out of the distal opening 436 of the handle body 402. As described above, the closure device 100 may include the anchor 108, cap 102, and fluid blocking member 104 all configured on the suture 106. The fluid-blocking component 104 can be an active biomaterial, such as polyethylene glycol (PEG), fibrin sealant, copolymer of glucosamine and N-acetylglucosamine, dextran (complex branched dextran (polysaccharide, polypeptide adhesive structure, adhesive protein containing L-3,4-dihydroxyphenylalanine (L-DOPA)), adhesive protein containing DOPA and phosphoserine, collagen, polyacrylic acid, crosslinked with allyl sucrose or allyl pentaerythritol, polyacrylic acid, crosslinked with divinyl glycol, acrylic resin polymer composed of methyl-2-cyanoacrylate units, or another fully bioabsorbable sealant material that can optionally be incorporated into a molded flexible substrate. The sealant material can be activated by fluids (e.g., blood or other fluids) present in the patient's tissue channels and can be protectively stored within the chamber of the sheath / actuator or delivery device until directly positioned on top of the cap 102.
[0150] Once advanced to the desired location, the sealant 104 can be exposed to blood or fluids, for example, by withdrawing the fluid barrier 104 and positioning it in direct contact with tissue where it can react upon contact with blood and other fluids. This reaction causes the fluid barrier 104 to swell and absorb blood and other fluids, binding to the surrounding tissue and cap 102. The sealant acts as an adhesive and helps “lock” the cap 102 in place on the blood vessel 10, and actively coagulates the entire inlet conduit 22. The chemical formulation, quantity, carrier matrix, and size of the fluid barrier 104 can be specifically selected to provide one or more of the functions of locking the sealant (e.g., cap 102) in place, thereby providing rapid-acting and leak-free dry closure and reducing tissue conduit leakage.
[0151] For example, the sealant can form a plug with a length of approximately 1 mm to approximately 10 mm, and can optionally be trimmed to a certain length in the patient's body along with the suture after deployment, or the adhesive component can extend the full length of the tissue canal and be trimmed to fit the patient. When the fluid barrier component 104 is formed of a matrix, the matrix can have an area of approximately 0.012 square inches to approximately 0.12 square inches, approximately 0.12 square inches to 0.6 square inches, or approximately 0.6 square inches to 1.0 square inches. The matrix material can be thin and flexible, allowing it to be wound around the suture in a delivery system for fitting within a tube for delivery to the implant site. This results in a fluid barrier component with a volume between approximately 0.004 and approximately 0.040 cubic inches, between approximately 0.040 and approximately 0.100 cubic inches, or between approximately 0.100 and approximately 0.400 cubic inches, which optionally includes a matrix containing a sealant such as PEG or other biocompatible materials.
[0152] The fluid barrier component 104 can be deployed such that it is arranged on the suture 106. Therefore, the fluid barrier component 104 can be deployed in a flowable composition without a carrier matrix, or can be formed partially or having a carrier matrix. For example, the fluid barrier component 104 can be arranged around the suture 106 in the form of a generally cylindrical component, can be incorporated into the suture 106 itself, can be incorporated into the cap 102, and combinations thereof or modifications thereof. Because the sealant 104 is positioned proximally relative to the cap 102, the sealant 104 can actively condense into the inlet channels 22, and optionally actively condense into all inlet channels 22 reaching the surface of the skin 16.
[0153] Figure 17A and Figure 17BAn expander assembly 470 is shown with an expander tube 456 having an expander bushing 458 that can be assembled onto the expander tube 456. The expander tube 456 can be inserted into a delivery sheath 440 to stretch the skin 16 and the opening in the access tube 22, thereby allowing insertion into the delivery sheath 440. The expander bushing 458 can be configured to selectively attach to and remove from the delivery sheath 440 via a sheath bushing 418. The expander bushing 458 may include a locking arm 459 that can selectively engage a receiving member 468 of the sheath bushing 418, for example, by interference fit or friction fit. The expander tube 456 and / or the expander bushing 458 may be formed of a biocompatible material, such as, but not limited to, nylon, polyethylene, high-density polyethylene (HDPE), or other polymeric materials.
[0154] The dilator tube 456 includes distal openings 455a and 455b facing distally and a proximal opening 461 facing proximally. The distal openings 455a and 455b communicate with passage 475 to form fluid markers (e.g., blood markers) to aid in positioning the dilator tube 456 within a body cavity. For example, fluid (e.g., blood) from within the body cavity is allowed to flow through one or both of the distal openings 455a and 455b and out through passage 475 and from the proximal opening 461 to indicate a specific depth. Although the distal openings 455a and 455b are shown as being located on opposite sides of the dilator tube 456, it will be understood that the location and number of openings can vary.
[0155] A mounting member 463 is arranged between the locking arms 459, which facilitates the mounting of the expander bushing 458 to the conveyor sleeve 440. The mounting member 463 is branched into a first leg 465a and a second leg 465b, each leg having a protrusion 467. The branched structure allows the mounting member 463 to flex when it engages with the conveyor sleeve 440, while the protrusion 467 has a frictional or interference fit within the sleeve bushing 418.
[0156] Figure 18A and Figure 18BThe illustrated delivery sheath 440 includes a sheath 441 for delivering an expander tube 456 and an implant assembly 426 through an inlet conduit 22. A sheath bushing 418 may be assembled onto the sheath 441 to allow selective attachment of other surgical instruments, such as the expander tube 456, to the delivery sheath 440. The sheath bushing 418 may include a receiving member 468 configured to receive and selectively retain surgical instruments on the delivery sheath 440, such as, but not limited to, a locking arm 459 and a locking member 420 of the expander bushing 458. The receiving member 468 may be a channel or passage formed by a wall 471. The proximal end 443 of the sheath 441 may cooperate with a valve 462 to prevent fluid backflow into the surgical instruments attached to the delivery sheath 440. The valve 462 is retained within the sheath bushing 418 by a valve cap 464, wherein a strain relief member 469 extends distally from the sheath bushing 418. One or more of the bushing 418, bushing 441, valve 462, valve cap 464, and strain relief member 469 may be joined together by overmolding bonding technology, or additionally by a combination of friction fit or interference fit and adhesive, thermal, chemical, or other bonding technologies.
[0157] When the expander assembly 470 is installed onto the delivery sleeve 440, the mounting member 463 passes through the valve cap 464 and the valve 462. With one or more ports 473 aligned with the distal opening 455, a fluid passage is formed to allow depth determination and positioning of the delivery sleeve 440. Additionally, markings 474 are provided on the sleeve 441 to provide depth indication of the delivery sleeve 440. For example, letters, numbers, or other symbols may be used to identify the insertion depth. In one configuration, first markings 474a may be spaced approximately 1 cm apart, with second markings 474b spaced approximately 0.5 cm apart from adjacent first markings 474a. It will be understood that one or more second markings 474b may be arranged between adjacent first markings 474a to vary the depth granularity. Additionally, the spacing of the first mark 474a may be in the range of approximately 0.1 cm to approximately 5 cm, approximately 0.25 cm to approximately 2.5 cm, approximately 0.5 cm to approximately 1 cm, less than approximately 5 cm, less than approximately 4 cm, less than approximately 3 cm, less than approximately 2 cm, less than approximately 1 cm, and less than approximately 0.5 cm.
[0158] like Figure 19A and Figure 19BAs shown, the handle assembly 400 can be selectively attached to the conveyor sleeve 440 by inserting the locking member 420 of the handle assembly 400 into the receiving member 418 of the conveyor sleeve to form the conveyor system 430. The locking member 420 may be made of an elastic material, such as flexible plastic, to allow the locking member 420 to flex when inserted into the receiving member 418. The locking member 420 may flex to disengage the hook-shaped end 422, thereby disengaging the handle assembly 400 from the conveyor sleeve 440. When the locking member 420 engages with the receiving member 468, the chamber nozzle 429 penetrates the valve 462 to provide passage to the sleeve 441 for conveying and deploying the closure device 100. When the conveyor system 430 is engaged to deploy the closure device 100, as Figure 19C As shown, the slider 450 can move toward the delivery sheath 440 in the distal direction, which can lead to the deployment of the anchor 108 of the closure device 100.
[0159] Figure 19D It shows Figure 19C A close-up view of the partially deployed closure device. The forked end 457 of the push line 454 deploys the anchor 108 of the closure device 100 from the delivery sleeve 441.
[0160] Method of inserting the handle assembly into the closing device
[0161] Figures 20A to 23C An example of a method for inserting a closure device using deployment system 430 is shown. First, expander tube 456 can be inserted into delivery sleeve 440. Expander tube 456 can be selectively attached to sleeve 441 by connecting expander bushing 458 to sleeve bushing 418 to maintain the position of expander tube 456 within delivery sleeve 440. Figures 20A to 20B The expander tube 456 can be used to stretch the opening of the skin 16 and the access tube 22 to allow placement of the closure device 100.
[0162] Next, the expander bushing 458 can be detached from the sheath bushing 418, and the expander tube 456 can be removed, as follows: Figure 21B As shown. The delivery sleeve 440 can be held in the inlet pipe 22. Figure 21C and Figure 21D A method for connecting the handle assembly 400 to the conveyor sleeve 440 is shown. The handle assembly 400 can be selectively connected to the conveyor sleeve 440 by engaging a connecting member of the handle assembly 400 with a receiving member or sleeve bushing 418 of the conveyor sleeve 440.
[0163] Once the handle assembly 400 is connected to the delivery sleeve 440, the user can press the proximal locking component 421 to unlock the slider 450, and push the slider in the distal direction toward the distal end 406 of the handle body 400, as shown. Figure 22 As shown. This causes the delivery system 430 to eject the anchor 108 into the lumen 12 of the blood vessel, allowing the anchor 108 to contact the lumen wall 14 and be positioned at the puncture or entry site 18. Once the slider 450 reaches the distal end 406, the anchor 108 should be ejected from the delivery system 430, with the cap 102 and the fluid blocking component 104 remaining in the support tube 442 of the implant assembly 426 within the delivery sheath 440.
[0164] Go to Figure 23A The slider 450 can be configured to slide along the elongated opening 408 until the slider portion 450b slides past the locking assembly 425, at which point the locking assembly 425 locks the slider portion 450b at the distal end of the elongated opening 408 (the locking assembly 425 may be formed together with the handle body 402, for example having a movable hinge connection to the handle body 402, or it may be a separate mechanism connected to or mounted to the handle body 402). Once the slider portion 450b is locked by the locking assembly 425, the user can press the slider portion 450a to release the interlocking end 466a from the interlocking end 466b, effectively releasing the slider portion 450a from the slider portion 450b. The slider portion 450a with the push wire bend 477 on which the push wire 452 is mounted can be moved proximally so that the push wire 452 retracts from the tissue in the proximal direction and enters the handle assembly 400.
[0165] After the anchor 108 is deployed, the user can engage the secondary slider 460 by pressing the plunger 476 and pushing the slider 460 toward the distal end 406 of the handle assembly 400 in the distal direction. Figure 23B The diagram shows the secondary slider 460 engaging the packing tube 454 (or a portion of the slider 438) and the packing cap 102 to eject the cap 102 from the delivery system 430. The delivery system 430 can then be pulled in a proximal direction to tighten the suture 106 and secure the anchor 108 and cap 102. After the anchor 108 and cap 102 are in place, the release button 424 can be engaged to release the suture 106 and closure device 100 from the delivery system 430, where the fluid blocking component 104 remains in the inlet conduit 22, as shown. Figure 23C As shown. Afterwards, the sutures can be trimmed at or below the level of the skin or tissue.
[0166] The articles “a,” “an,” and “the” are intended to indicate the presence of one or more elements in the preceding description. The terms “comprising,” “including,” and “having” are intended to be inclusive and indicate that additional elements may be present in addition to those listed. Furthermore, it should be understood that references to “an embodiment” or “an embodiment” in this disclosure are not intended to be construed as excluding the existence of additional embodiments that also incorporate the described features. As will be understood by those skilled in the art as covered by embodiments of this disclosure, the numbers, percentages, ratios, or other values described herein are intended to include that value, as well as other values that are “about” or “approximate” to said value. Therefore, the values should be interpreted broadly enough to cover values that are at least sufficiently close to said value to perform the desired function or achieve the desired result. The values include at least the variations expected in a suitable manufacturing or production process and may include values within 5%, 1%, 0.1%, or 0.01% of said value.
[0167] Those skilled in the art will recognize that, in view of this disclosure, equivalent constructions do not depart from the spirit and scope of this disclosure, and various changes, substitutions, and modifications can be made to the embodiments disclosed herein without departing from the spirit and scope of this disclosure. Equivalent constructions including the functional "device plus function" clause are intended to cover structures described herein that perform the recited functions, including both structural equivalents operating in the same manner and equivalent structures providing the same function. The applicant's explicit intent is not to invoke device plus function or otherwise claim the function of any of the claims, except where the phrase "device for..." appears with the associated function. Every addition, deletion, and modification to the embodiments falling within the meaning and scope of the claims will be included in the claims.
[0168] As used herein, the terms “approximately,” “about,” and “substantially” refer to quantities that are close to still performing the intended function or achieving the intended result. For example, the terms “approximately,” “about,” and “substantially” can refer to quantities that are less than 5%, less than 1%, less than 0.1%, and less than 0.01% of the stated quantity. Furthermore, it should be understood that any direction or frame of reference in the foregoing description is only a relative direction or relative motion. For example, any references to “up” and “down,” or “above” or “below,” are merely descriptions of the relative position or relative motion of the relevant elements.
[0169] The following are some further exemplary embodiments of the present invention. These are presented by way of example only and are not intended to limit the scope of the invention in any way. Furthermore, any exemplary embodiment may be combined with one or more exemplary embodiments.
[0170] Example 1. A vascular closure device comprising a bioabsorbable vascular closure device for immediate hemostasis at a perforation site in a blood vessel wall, the closure device comprising: an intravascular anchor including one or more suture attachment points; an outer vascular cap including an inner lumen; a sealant; and a suture connected to at least one of the one or more suture attachment points of the intravascular anchor and passing through the inner lumen of the outer vascular cap and through the sealant to connect the intravascular anchor to the outer vascular cap and to the sealant, wherein each of the intravascular anchor, the outer vascular cap, the sealant and the suture is formed of a bioabsorbable material.
[0171] Example 2. The vascular closure device according to Example 1, wherein the vascular anchor includes an elongated body, the elongated body including a flexible member and a keel.
[0172] Example 3. A vascular closure device according to any one of Examples 1 to 2, wherein the vascular cap is formed of a flexible material.
[0173] Example 4. A vascular closure device according to any one of Examples 1 to 3, wherein the sealant comprises polyethylene glycol (PEG).
[0174] Example 5. A vascular closure device according to any one of Examples 1 to 4, wherein the suture includes a distal suture portion and a proximal suture portion.
[0175] Example 6. A vascular closure device according to any one of Examples 1 to 5, wherein the diameter of the inner lumen of the vascular cap is smaller than the diameter of the distal suture portion.
[0176] Example 7. A vascular closure device according to any one of Examples 1 to 6, wherein the vascular anchor comprises a material selected from polyglycolic acid (PGA), poly-L-lactic acid (PLLA), polycaprolactone (PCL), poly-DL-lactic acid (PDLLA), polytrimethylene carbonate (PTMC), and poly(p-dioxanone) (PPDO).
[0177] Example 8. A vascular closure device according to any one of Examples 1 to 7, wherein the vascular anchor includes a plurality of ribs radiating from the keel to the raised edge of the elongated body.
[0178] Example 9. A vascular closure device according to any one of Examples 1 to 8, wherein the sealant can expand to 4 times its original size when introduced into the fluid.
[0179] Example 10. A vascular closure device for immediate hemostasis at a perforation site in a blood vessel wall, the closure device comprising: an intravascular anchor including one or more suture attachment points; an outer vascular cap including an inner lumen; a sealant including an inner lumen; and a suture connected to at least one of the one or more suture attachment points of the intravascular anchor and passing through the inner lumen of the outer vascular cap and through the inner lumen of the sealant to connect the intravascular anchor to the outer vascular cap and to the sealant, wherein the suture includes a proximal suture portion and a distal suture portion, wherein the diameter of the distal suture portion is larger than the diameter of the inner lumen of the outer vascular cap, wherein the distal suture portion creates an interference fit to lock the outer vascular cap above the perforation site, wherein each of the intravascular anchor, the outer vascular cap, the sealant, and the suture is formed of a bioabsorbable material.
[0180] Example 11. A vascular closure device according to any one of Examples 10, wherein the vascular cap is formed of a flexible material.
[0181] Example 12. A vascular closure device according to any one of Examples 10 to 11, wherein the suture is a braided suture.
[0182] Example 13. A vascular closure device according to any one of Examples 10 to 12, wherein the sealant is inserted into the suture at a position proximal to the outer cap of the vascular vessel.
[0183] Example 14. A vascular closure device according to any one of Examples 10 to 13, wherein the sealant, when activated, locks the vascular cap in place and causes the entry channel at the perforation site to coagulate, thereby providing immediate hemostasis.
[0184] Example 15. A vascular closure device according to any one of Examples 10 to 14, wherein the vascular anchor includes an elongated body that includes a flexible member.
[0185] Example 16. A vascular closure device according to any one of Examples 10 to 15, wherein the vascular anchor includes a raised keel located on the central axis of the elongated body and spanning the length of the elongated body.
[0186] Example 17. A vascular closure device according to any one of Examples 10 to 16, wherein the raised keel includes one or more suture attachment points.
[0187] Example 18. A vascular closure device according to any one of Examples 10 to 17, wherein the sealant comprises polyethylene glycol (PEG).
[0188] Example 19. An intravascular anchor for an intravascular closure device for immediate hemostasis at a perforation site in a blood vessel wall, the intravascular anchor comprising an elongated body including a flexible member for conforming to the blood vessel wall and a keel having one or more suture attachment points, wherein the keel is an elongated member centrally positioned along the central axis of the elongated body, wherein the intravascular anchor comprises a bioabsorbable material selected from polyglycolic acid (PGA), poly-L-lactic acid (PLLA), polycaprolactone (PCL), poly-DL-lactic acid (PDLLA), polytrimethylene carbonate (PTMC), and polydioxanone (PPDO).
[0189] Example 20. The intravascular anchor of claim 19, wherein the elongated body includes a plurality of ribs radiating from the keel to a raised edge forming the periphery of the elongated body.
[0190] This invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments should be considered in all respects as illustrative rather than restrictive. Therefore, the scope of the invention is indicated by the appended claims rather than by the foregoing description. All modifications within the equivalent meaning and scope of the claims are to be included within their scope. It should be further understood that although the invention has been described with respect to vascular closure, it is conceivable that the closure element of the invention can be used to close other openings within the body, such as PFO openings, or openings formed in organs such as the stomach, for certain surgical procedures.
Claims
1. A vascular closure device for hemostasis at a perforation site in a blood vessel wall, the closure device comprising: Intravascular anchors include one or more suture attachment points; A disc-shaped vascular cap, including an inner lumen, the vascular cap extending beyond the diameter of the perforation portion and configured to cover and seal the perforation portion; A sealant is disposed near the outer cap of the vascular system and configured to cause the inlet conduit at the perforation site to solidify. as well as A suture is attached to at least one of the one or more suture attachment points of the intravascular anchor, and passes through the lumen of the outer vascular cap and through the sealant to connect the intravascular anchor to the outer vascular cap and to the sealant. Each of the intravascular anchor, the outer vascular cap, the sealant, and the suture is made of a bioabsorbable material. The intravascular anchor, the outer vascular cap, and the sealant are disposed within a handle, which is configured to be attached to the delivery sleeve before the intravascular anchor, the outer vascular cap, and the sealant are delivered to the vessel wall through an unfolded delivery sleeve.
2. The vascular closure device according to claim 1, wherein, The intravascular anchor includes an elongated body, which comprises a flexible component and a keel.
3. The vascular closure device according to claim 1, wherein, The vascular cap is formed of an elastomeric material.
4. The vascular closure device according to claim 1, wherein, The sealant includes polyethylene glycol.
5. The vascular closure device according to claim 1, wherein, The suture includes a distal suture portion and a proximal suture portion.
6. The vascular closure device according to claim 5, wherein, The diameter of the inner lumen of the vascular cap is smaller than the diameter of the distal suture portion.
7. The vascular closure device according to claim 1, wherein, The intravascular anchor includes at least one of polyglycolic acid, poly-L-lactic acid, polycaprolactone, poly-DL-lactic acid, polytrimethylene carbonate, and polydioxanone.
8. The vascular closure device according to claim 2, wherein, The intravascular anchor includes multiple ribs radiating from the keel to the raised edge of the elongated body.
9. The vascular closure device according to claim 1, wherein, The sealant is configured to expand to four times its original size when introduced into the fluid.
10. The vascular closure device according to claim 1, wherein, The sealant includes an inner cavity; The suture includes a proximal suture portion and a distal suture portion, wherein the diameter of the distal suture portion is larger than the diameter of the lumen of the vascular cap; and The distal suture portion is configured to interfere with the vascular cap to lock the vascular cap above the perforation site.
11. The vascular closure device according to claim 10, wherein, The stitching is braided stitching.
12. The vascular closure device according to claim 10, wherein, The sealant is inserted into the suture near the outer cap of the vascular vessel.
13. The vascular closure device according to claim 10, wherein, The sealant is configured to lock the vascular cap in place and provide substantially immediate hemostasis.
14. The vascular closure device according to claim 2, wherein, The keel is located on the central axis of the slender body and spans the length of the slender body.
Citation Information
Patent Citations
Intra-arterial occluder
US20020019648A1
Tissue puncture closure device with track plug
US20070032824A1
Rapidly eroding anchor
US20100179589A1
Sealing mechanism for closure devices
US20140058439A1
Hemostatic vessel puncture closure with filament lock
US5700277A
